Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TZ-161 (eletriptan) in early acute spinal cord injury
2023-509207-33-01Phase 2Authorised
- Sponsor
- TechnoPhage
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, single-blind trial in spinal cord injury (SCI) comparing Relert plus standard of care with Standard of care alone (2 arms). Primary endpoint: Treatment-emergent adverse events and serious adverse events. Planned start Jun 2024; status: authorised.
02
Drugs
Relert
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on 2023-509207-33-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509207-33-01.